Research Article

Measurement of the Red Blood Cell Distribution Width Improves the Risk Prediction in Cardiac Resynchronization Therapy

Table 3

Differences in baseline characteristics in patients with increased or decreased RDW levels.

RDW < 13.35%RDW > 13.35% value
()()

Clinical variables
 Age (years)67 (59–71)68 (62–74)0.08
 Male gender43 (81)67 (82)0.81
 BMI (kg/m2)27 (24–30)27 (23–29)0.40
 Ischemic30 (56)47 (58)0.87
 LBBB49 (92)61 (75)0.005
 CRT-D11 (20)11 (13)0.27
 Opt. lead position41 (77)57 (70)0.37
 QRS (msec)155 (134–180)164 (146–189)0.04
 LVEF (%)28 (24–33)25 (23–32)0.43
 LVESV (mL)202 (147–276)214 (153–267)0.71
 LVEDV (mL)285 (234–341)312 (250–361)0.29
 NYHA III. IV40 (75)75 (92)0.005
 Hypertension29 (54)45 (55)0.92
 Hyperlipidemia11 (20)21 (25)0.49
 Diabetes m.15 (28)35 (43)0.08
 ACEi/ARB 53 (100)75 (92)0.04
 BB 49 (92)71 (87)0.37
 MRI 37 (69)57 (70)0.94
Laboratory data
 Hematocrit (%)43 (39–45)41 (37–43)0.11
 NT-proBNP (pg/mL)1817 (691–3086)3581 (2007–6232)<0.0001
 Creatinine (μmol/L)92 (74–121)112 (85–135)0.007

Data are expressed as medians with interquartile ranges for continuous variables and as event numbers with percentages for categorical variables. For the comparison of continuous data, we used the Mann-Whitney test, whereas the chi squared test was applied for the comparison of the categorical variables. BMI = body mass index; Ischemic = ischemic etiology of the heart failure; LBBB = left bundle branch block; CRT-D = cardiac resynchronization therapy with implantable cardioverter defibrillator; Opt. lead position = lateral or posterolateral position; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume; LVEDV = left ventricular end diastolic volume; NYHA III, IV = New York Heart Association classification 3-4; ACEi/ARB = angiotensin convertase inhibitor/angiotensin receptor blocker; BB = beta-blocker; MRI = mineralocorticoid receptor inhibitor; NT-proBNP = N-terminal of the prohormone brain natriuretic peptide; RDW = red blood cell distribution width.